Q32 Bio Inc. held its Annual Meeting of Stockholders on June 13, 2025. During the meeting, stockholders approved an amendment to the Company's Restated Certificate of Incorporation to limit the liability of certain officers. Additionally, stockholders elected David Grayzel, M.D., Isaac Manke, Ph.D., and Diyong Xu as Class I directors. Stockholders also voted for "One Year" as the preferred frequency of future advisory votes on executive compensation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.